The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Syfovre
Pegcetacoplan · PEGCETACOPLAN 15 mg/.1mL · Injection, Solution · Intravitreal · Apellis Pharmaceuticals, Inc.
NDC 73606-0020-12 · 1 VIAL, GLASS in 1 CARTON / 3 mL in 1 VIAL, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Bachem AGSwitzerlandapi manufacture
- Eurofins Advantar Laboratories, LLCUnited Statesanalysis
- Eurofins Lancaster Laboratories, LLCUnited Statesanalysis
- api manufacture
- Lifecore Biomedical Operating Company, Inc.United Statesanalysis
- Lifecore Biomedical, LLCUnited Statesmanufacture
- Micro Measurement Laboratories, Inc.United Statesanalysis
- Packaging Coordinators, LLCUnited Statespack
- West Services and Solutions LLCUnited Statesanalysis
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $3,001.44 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Empaveli
Regulatory
- Application
- NDA217171
- TE code
- —
- Approval date
- Feb 17, 2023
- Patents / exclusivity
- 13 patents, 2 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NCE | May 14, 2026 |
| exclusivity | NP | Feb 22, 2026 |
| patent | 12458695 | Dec 14, 2038 |
| patent | 11903994 | Feb 22, 2037 |
| patent | 12528836 | Oct 7, 2036 |
| patent | 10875893 | Nov 15, 2033 |
| patent | 10035822 | Nov 15, 2033 |
| patent | 11292815 | Nov 15, 2033 |
| patent | 10125171 | Aug 2, 2033 |
| patent | 11661441 | Jan 13, 2033 |
| patent | 7888323 | Dec 4, 2027 |
| patent | 7989589 | Dec 4, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Pegcetacoplan (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | PEGCETACOPLAN 1080 mg/20mL | Jul 15, 2026 | Sep 2, 2026 |
| Apellis Pharmaceuticals, Inc. | PEGCETACOPLAN 15 mg/.1mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Syfovre — NDC 73606-0020-12," retrieved September 3, 2026, https://drugdashboards.com/drug/73606002012.
Free to cite with attribution — see how the data is put together.